Zhaoliang Su，PhD，Professor, Vice Dean of the School of Life Sciences，Jiangsu University, primarily engaged in decoding the regional immune characteristics of the heart and their relationship with heart diseases.
ADDRESS International Genome Center, Jiangsu University
301 Xuefu Road
Zhenjiang, Jiangsu 212013,
China
Tel:86-511-88780266
E-mail:SZL30@yeah.net or szl30@ujs.edu.cn
EDUCATION
2008~2011 Ph.D degree, Jiangsu University, Clinical Laboratory Diagnostics
2005~2008 Master degree, Jiangsu University, Clinical Laboratory Diagnostics
1998~2003 Bachelor degree, Jiangsu University, Medical Examination
WORKING EXPERIENCE
2018 ~ now International Genome Center, Jiangsu University
2003 ~ 2018 Medical School, Jiangsu University
2009 ~ 2010 Visiting Scholarship, the University of Western Ontario, Lawson health research institute, Canada
TITLES
(1)Young Leading Talent of "333 Project" of Jiangsu Province, 2016.
(2)Outstanding Ph.D. Thesis of Jiangsu Province, 2012.
(3)Excellent Young Scholar of the Chinese Society for Immunology, 2012.
(4)Core Teacher of "Blue Project" of Jiangsu Province, 2012.
(5)Cultivation Targets of "Six Talents" of Jiangsu Province, 2013, 2019.
(6)Outstanding Health Talent of Jiangsu Province, 2014.
(7)Technical Backbone of "169 Project" of Zhenjinag, 2016, 2021.
(8)Cultivation Candidate of Young Academic Leader in Jiangsu University, 2013.
PROFESSIONAL APPOINTMENTS
2019~ now Executive Director, International Genome Center, Jiangsu University
2017~2018 Professor, Department of Immunology, Jiangsu University
2013~2017 Associate Professor, Department of Immunology, Jiangsu University
2008 ~ 2012 Lecturer, Department of Immunology, Jiangsu University
2003 ~ 2008 Research Assistant, Department of Immunology, Jiangsu University
ACADEMIC APPOINTMENTS
（1）Director of the Youth Workers' Federation of Jiangsu Immunology Society
（2）Executive Director of Jiangsu Immunology Society
（3）Standing Committee Member of the Youth Workers' Federation of the Chinese Society for Immunology
（4）Deputy Secretary-General of the Cell Therapy Branch of the Chinese Society of Biotechnology
（5）Member of the Immunocytology Branch of the Chinese Society for Cell Biology
（6）Member of American Association of Immunologists
（7）Member of Society for Leukocyte Biology (SLB)
STUDENT CULTIVATION
(1)Supervisor of outstanding Ph.D. Thesis at Jiangsu University, 2020
(2)Supervisor of outstanding Master Thesis at Jiangsu University, 2021
(3)Excellent Guidance Teacher for the 7th National Undergraduate Basic Medical Innovation Research and Experimental Design, 2021
GRANTS
(1) National Natural Science Foundation of China, Mechanism Study of EpAT-derived C3aR1(+)CMC-released Lgals3 in Promoting Myocardial Fibrosis after MI, 32370984, 2024-2027, 500,000 CNY, under research.
(2) National Natural Science Foundation of China, Research of reHMGB1 Induced NKp46+ILC3 Amplification and IL-22 Secretion in Regulating Myocardial Fibrosis in EAM Mice, 81871244, 2019-2022, 560,000 CNY, completed.
(3) National Natural Science Foundation of China, Mechanism Study of ANGII/AT1R Regulated Myocardial Infiltration of Ly6Chi Monocytes Contributing to Mouse EAM Occurrence, 81671567, 2017-2020, 600,000 CNY, completed.
(4) National Natural Science Foundation of China, Mechanism Study of HMGB1 Regulated Mφ Polarization Contributing to Th17-mediated Mouse EAM Occurrence, 81370084, 2014-2017, 700,000 CNY, completed.
(5) National Natural Science Foundation of China (Youth Project), Mechanism Study of HMGB1 Induced Th17 Cell Proliferation in EAM Mice, 81001319, 2011-2013, 220,000 CNY, completed.
(6) Social Development Key Project of Jiangsu Province, Research on Screening Targets for Promoting Myocardial Cell Regeneration Based on CRM and Strategies in Comprehensive Prevention and Treatment of Heart Diseases, BE2019700, 2019-2022, 2,000,000 CNY, completed.
(7) Policy Guidance Plan of Jiangsu Province (Introduction of Foreign Experts), Research on the Basics and Clinics of Cardiovascular Diseases, BX2019100, 2019-2022, 500,000 CNY, under research.
(8) igh-level Foreign Expert Introduction Plan of Ministry of Science and Technology, Research on Heart Injury and Repair Based on the Regulation of the Cardiac Microenvironment, G2022014014156L, 2022-2023, 110,000 CNY, under research.
(9) Health Commission Key Project of Jiangsu Provincial, Research on Screening Targets for Promoting Myocardial Regeneration Based on Multi-omics and Mathematical Models, and New Strategies in the Prevention and Treatment of Heart Diseases, ZD2021009, 2022-2024, 200,000 CNY, under research.
(10) China Scholarship Council, International Cooperation and High-level Talent Training Project with Canada, Research on Heart Injury and Repair Strategies Based on the Regulation of the Immune Microenvironment, 2023-2025, 100,000 CNY, under research.
(11) "Six Talents" Peak Project of Jiangsu Province, Mechanism Study of Intestinal Microbial Influence on the Interaction between CD64+MertK+CRM and Cardiomyocytes in Regulating Cardiac Regeneration, 2019-WSN-122, 2020-2022, 40,000 CNY, under research.
(12) 333 Research Project Funding Plan of Jiangsu Province, Research on reHMGB1 Induced NKp46+ILC3 Amplification and IL-22 Secretion in Regulating Myocardial Fibrosis, BRA2018016, 2018-2020, 200,000 CNY, completed.
(13) Policy Guidance Plan of Zhenjiang - International Scientific and Technological Cooperation - Innovative International Service, International Industry-University-Research Cooperation and Application of Scientific and Technological Achievements in "Diagnosis and Treatment Strategies of Heart Regeneration and Repair", GJ2020010, 2020-2022, 200,000 CNY, completed.
(14) Crossing Research Project, Industry-University-Research Service Based on Flow Analysis Technology, Huaixi Biotechnology Company of Jiangsu Province, 2022-2027, 3,000,000 CNY, under research.
(15) Crossing Research Project, Evaluation of the Impact of mRNA Vaccines on the Immune Microenvironment, Shenji Biotechnology Company of Jiangsu Province, 2021-2025, 990,000 CNY, under research.
(16) Postdoctoral Special Support Project of China, Research on the Molecular Mechanism of HMGB1 in Regulating Mφ Differentiation/Polarization in EAM Mice, 2013T60508, 2013-2015, 150,000 CNY, completed.
(17) Postdoctoral Foundation General Project of China, Research on the Mechanism of HMGB1/LPS in Regulating Th17 Cells Involved in Bone Resorption of Periodontal Disease, 2012M511705, 2012-2014, 50,000 CNY, completed.
(18) "Six Talents" Peak Project of Jiangsu Province, Mechanism and Intervention Study of HMGB1 in Regulating MDSC Involved in Immune Escape of Breast Cancer Cells, 2014-2016, 30,000 CNY, completed.
(19) Women and Children Special Project of Health and Family Planning Commission of Jiangsu Province, Screening and Clinical Application Research of cicrRNAs for Ovarian Cancer Diagnosis, F201511, 2015-2018, 50,000 CNY, completed.
(20) International Cooperation and Exchange Project of Zhenjiang, GJ2010007, Development of a Vaccine Based on Gingival Porphyrin rag Gene Epitope, 2010-2012, 100,000 CNY, completed.
(21) University Natural Science Foundation of Jiangsu Province, 09KJB310001, Pathogenic Mechanism of Th1 and Th17 in EAM and Intervention Effect of IL-27, 2009-2011, 30,000 CNY, completed.
(22) Doctoral Innovation Fund of Jiangsu Province, CX09B_217Z, Relationship between Th1 and Th17 and the Occurrence and Development of EAM, and the Intervention Effect of IL-27, 2009-2011, 25,000 CNY, completed.
RESEARCH AWARDS AND PATENTS
(1)Su Zhaoliang, Xu Huaxi, Jiao Zhijun, Chen Jianguo, Sun Yingkun, Zhou Chenglin, Chen Deyu. Basic and Clinical Research on Th17 Cells and Related Factors in the Occurrence of Autoimmune Diseases. Third Prize of Science and Technology Progress Award of Jiangsu Province. 2014.
(2) Jiao Zhijun, Wang Wenhong, Xu Huaxi, Su Zhaoliang, Xu Min, Wang Shengjun, Li Jing. Research on the Pathogenesis of Rheumatoid Arthritis Based on Cellular Immunoregulation. Third Prize of Science and Technology Progress Award of Jiangsu Province. 2012.
(3) Xu Wenlin, Shen Huiling, Zhu Xiaolan, Cheng Jian, Su Zhaoliang, Lin Lin, Chi Huamao. Establishment of In Vivo and In Vitro Models of Tumor Drug Resistance and Mechanism Research. Third Prize of Science and Technology Progress Award of Jiangsu Province. 2015.
(4) Yu Bin, Zhang Pan, Yang Yuqi, Su Zhaoliang, Liu Jianbing, Wang Huiyan, Wang Huaiyan, Lu Beiyi, Zhou Qin, Chen Yingping. Integrated Innovation and Translational Application of the Precision Medicine Platform in the Prevention of Birth Defects. Second Prize of the Natural Science Award of Maternal and Child Health Science and Technology. 2021.
(5) Su Zhaoliang, Kong Fanzhi, Zhu Haitao, Liu Yueqin, Xu Huaxi. Basic and Clinical Research on HMGB1 Regulating Th17 Cells Involved in the Occurrence of EAM. Second Prize of Science and Technology Progress Award of Zhenjiang. 2016.
(6) Jiao Zhijun, Wang Wenhong, Xu Huaxi, Su Zhaoliang, Xu Min. Research on the Pathogenesis of Rheumatoid Arthritis Based on Cellular Immunoregulation. Second Prize of Science and Technology Progress Award of Zhenjiang. 2012.
(7) Kong Fanzhi, Su Zhaoliang, She Peng, Qian Liangyu, Zhou Chenglin. Research on Diagnosis Reagents and Universal Vaccines for Outer Membrane Proteins of Porphyromonas gingivalis. Third Prize of Science and Technology Progress Award of Zhenjiang. 2011.
(8) Fang Jie, Su Zhaoliang, Zhao Xiaosu, Zhang Xiaofei, Xu Zhengfang. Research on the Immunopathogenic Mechanism of Pregnancy-induced Hypertensive Diseases and Related Diseases. Third Prize of Science and Technology Progress Award of Zhenjiang. 2013.
(9) Chen Jianguo, Wang Shengjun, Liu Yingzhao, Su Zhaoliang, Xu Huaxi. Distribution and Structural Analysis of Class I Integrons of Gram-negative Rods and Their Relationship with Drug Resistance. Second Prize of Science and Technology Progress Award of Zhenjiang. 2009.
(10) Chen Jianguo, Liu Yingzhao, Wang Shengjun, Su Zhaoliang, Gu Hongbing. Study on Drug Resistance Mechanism and Epitope Nucleic Acid Vaccine of Pseudomonas aeruginosa. Second Prize of Science and Technology Progress Award of Zhenjiang. 2011.
(11) Series of studies on pregnancy complications based on the prevention and control of birth defects. Jiangsu Medical Association. Ranked third.
(12) Su Zhaoliang, Zhou Chenglin, Sun Caixia, Kong Fanzhi, Liu Yanfang, Zheng Dong, Tong Jia, Wang Shengjun, Xu Huaxi. Monoclonal Antibody Antagonizing HMGB1 B Box and Related Application. Patent No. 201210016550.3 (Granted).
PUBLICATIONS (50+)
(1)Chen R, Zhang S, Liu F, Xia L, Wang C, Sandoghchian Shotorbani S, Xu H, Chakrabarti S, Peng T, Su Z. Renewal of embryonic and neonatal-derived cardiac-resident macrophages in response to environmental cues abrogated their potential to promote cardiomyocyte proliferation via Jagged-1-Notch1. Acta Pharm Sin B. 2023;13(1):128-141.
(2)Jin J, Wang Y, Liu Y, Chakrabarti S, Su Z. Cardiac resident macrophages: spatiotemporal distribution, development, physiological functions, and their translational potential on cardiac diseases. Acta Pharm Sin B. 2023(Accepted)
(3)Ji XY, Zheng D, Ni R, Wang JX, Shao JQ, Vue Z, Hinton A Jr, Song LS, Fan GC, Chakrabarti S, Su ZL, Peng TQ. Sustained over-expression of calpain-2 induces age-dependent dilated cardiomyopathy in mice through aberrant autophagy. Acta Pharmacol Sin. 2022;43(11):2873-2884
(4)Chen R, He J, Su Z, Chen J. A plant immune protein fights against cancer. Trends Biochem Sci. 2022;47(12):996-998.
(5)Chen J, Su Z, Wang G. Dietary reprogram of macrophages for cell competition: a promising strategy for malignant cancer control. Signal Transduct Target Ther. 2023;8(1):411(co-first author)
(6)Li J, Xia L, Liu F, Tian Y, Chen R, Su Z. lncRNA187415.1 silence in BCAMs ameliorated breast cancer progression by blocking C/EBPβ-lncRNA187415.1-CISH axis and reversing pro-tumor characteristic of BCAMs. Clin Transl Med. 2021;11(5):e407.
(7)Wan J, Wu Y, Huang L, Tian Y, Ji X, Abdelaziz MH, Cai W, Dineshkumar K, Lei Y, Yao S, Sun C, Su Z, Wang S, Xu H. ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8+ T cells. Cancer Lett. 2021;502:34-43.
(8)Lu H, Zhang Z, Barnie PA, Su Z. Dual faced HMGB1 plays multiple roles in cardiomyocyte senescence and cardiac inflammatory injury. Cytokine Growth Factor Rev. 2019;47:74-82
(9)Jin J, Jiang Y, Chakrabarti S, Su Z. Cardiac Mast Cells: A Two-Head Regulator in Cardiac Homeostasis and Pathogenesis Following Injury. Front Immunol. 2022;13:963444.
(10)Lu H, Chen R, Barnie PA, Tian Y, Zhang S, Xu H, Chakrabarti S, Su Z. Fibroblast transdifferentiation promotes conversion of M1 macrophages and replenishment of cardiac resident macrophages following cardiac injury in mice. Eur J Immunol. 2020;50(6):795-808.
(11)Zhang S, Chen R, Chakrabarti S, Su Z. Resident macrophages as potential therapeutic targets for cardiac ageing and injury. Clin Transl Immunology. 2020;9(8): e1167
(12)Lu H, Wu Y, Shao X, Zhou S, Jiang Y, Chen R, Zong G, Xu H, Su Z. ANG II facilitated CD11+Ly6Chi cells reprogramming into M1-like macrophage through Erk1/2 or p38-Stat3 pathway and involved in EAM. J Leukoc Biol. 2018; 103(4):719-730
(13)Chen R, Liu F, Xia L, Che N, Tian Y, Cao Y, Zhang S, Xu H, Su Z. B10 cells decrease fibrosis progression following cardiac injury partially by IL-10 production and regulating hyaluronan secretion. J Leukoc Biol. 2022;111(2):415-425.
(14)Zhou L, Tian Y, Guo F, Yu B, Li J, Xu H, Su Z. LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize p53 activation and alleviate breast cancer development. Cancer Immunol Immunother. 2020;69(5):835-846
(15)Tian Y, Gong X, Qin D, Cao Y, Zhang S, Xia L, Liu F, Su Z. S1PR1-dependent migration of ILC3s from intestinal tissue to the heart in a mouse model of viral myocarditis. J Leukoc Biol. 2023;114(2):154-163
(16)Che Y, Tian Y, Chen R, Xia L, Liu F, Su Z. IL-22 ameliorated cardiomyocyte apoptosis in cardiac ischemia/reperfusion injury by blocking mitochondrial membrane potential decrease, inhibiting ROS and cytochrome C. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(9):166171
(17)Gong X, Xia L, Su Z. Friend or foe of innate lymphoid cells in inflammation-associated cardiovascular disease. Immunology. 2021;162(4):368-376.
(18)Tian Y, Cao Y, Chen R, Jing Y, Xia L, Zhang S, Xu H, Su Z. HMGB1 A box protects neurons by potently inhibiting both microglia and T cell-mediated inflammation in a mouse Parkinson's disease model. Clin Sci (Lond). 2020;134(15):2075-2090.
(19)Tian Y, Chen R, Su Z. HMGB1 is a Potential and Challenging Therapeutic Target for Parkinson's Disease. Cell Mol Neurobiol. 2023;43(1):47-58.
(20)Chen R, Cao Y, Tian Y, Gu Y, Lu H, Zhang S, Xu H, Su Z. PGE2 ameliorated viral myocarditis development and promoted IL-10-producing regulatory B cell expansion via MAPKs/AKT-AP1 axis or AhR signaling. Cell Immunol. 2020;347:104025.
(21)Cao Y, Tian Y, Liu Y, Su Z. Reg3β: A Potential Therapeutic Target for Tissue Injury and Inflammation-Associated Disorders. Int Rev Immunol. 2022;41(2):160-170
(22)Zhao Y, Shao Q, Zhu H, Xu H, Long W, Yu B, Zhou L, Xu H, Wu Y, Su Z. Resveratrol ameliorates Lewis lung carcinoma-bearing mice development, decreases granulocytic myeloid-derived suppressor cell accumulation and impairs its suppressive ability. Cancer Sci. 2018;109(9):2677-2686.
Reviewer for Grants
National Science Center (NCN) of Poland
National Natural Science Foundation of China
National Postdoctoral Science Foundation of China
Editor
World Chinese Journal of Digestion (Chinese)
Guest editor
Current Protein & Peptide Science Executive
Reviewer for journals
Acta Biomaterialia
Canadian Journal of Cardiology
Frontiers in Genetics
Frontiers in Pharmacology
Acta Pharm Sin B
J Leukoc Biol
Cell Immunol
Hum Immunol
BMC Immunol
Scand J Immunol
J Cell Mol Med
Int J Mol Sci
Biomed Pharmacother
Cells
Int Immunopharmacol
Int J Biol Sci
Biomolecules
Macromol Biosci
Life
